Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Walk Assist Device to Improve Community Ambulation
Development of Walk Assist Device to Improve Community Ambulation
Status: Enrolling
Updated:  4/3/2018
Rehabilitation Institute of Chicago
mi
from
Chicago, IL
Walk Assist Device to Improve Community Ambulation
Development of Walk Assist Device to Improve Community Ambulation
Status: Enrolling
Updated: 4/3/2018
Rehabilitation Institute of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Studies of Heritable Disorders of Connective Tissue
Clinical and Molecular Manifestations of Heritable Disorders of Connective Tissue
Status: Enrolling
Updated:  4/4/2018
National Institute of Aging, Clinical Research Unit
mi
from
Baltimore, MD
Studies of Heritable Disorders of Connective Tissue
Clinical and Molecular Manifestations of Heritable Disorders of Connective Tissue
Status: Enrolling
Updated: 4/4/2018
National Institute of Aging, Clinical Research Unit
mi
from
Baltimore, MD
Click here to add this to my saved trials
Treatment for Word Retrieval Impairments in Aphasia
Communication Outcomes for Naming Treatments in Aphasia
Status: Enrolling
Updated:  4/4/2018
Old Dominion University Speech and Hearing Clinic
mi
from
Norfolk, VA
Treatment for Word Retrieval Impairments in Aphasia
Communication Outcomes for Naming Treatments in Aphasia
Status: Enrolling
Updated: 4/4/2018
Old Dominion University Speech and Hearing Clinic
mi
from
Norfolk, VA
Click here to add this to my saved trials
The PTC124 (Ataluren) Clinical Trial for Duchenne Muscular Dystrophy: Exploration of the Experiences of Parents, Clinician Researchers, and the Industry Sponsor
The PTC124 (Ataluren) Clinical Trial for Duchenne Muscular Dystrophy: Exploration of the Experiences of Parents, Clinician Researchers, and the Industry Sponsor
Status: Enrolling
Updated:  4/4/2018
National Human Genome Research Institute (NHGRI), 9000 Rockville Pike
mi
from
Bethesda, MD
The PTC124 (Ataluren) Clinical Trial for Duchenne Muscular Dystrophy: Exploration of the Experiences of Parents, Clinician Researchers, and the Industry Sponsor
The PTC124 (Ataluren) Clinical Trial for Duchenne Muscular Dystrophy: Exploration of the Experiences of Parents, Clinician Researchers, and the Industry Sponsor
Status: Enrolling
Updated: 4/4/2018
National Human Genome Research Institute (NHGRI), 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Pregabalin in Preventing Acute Pain Syndrome in Patients Receiving Paclitaxel
RC11C3, Pilot Placebo-controlled Evaluation of Pregabalin as a Means to Prevent the Paclitaxel-Associated Acute Pain Syndrome
Status: Enrolling
Updated:  4/4/2018
Cancer Center of Kansas
mi
from
Wichita, KA
Pregabalin in Preventing Acute Pain Syndrome in Patients Receiving Paclitaxel
RC11C3, Pilot Placebo-controlled Evaluation of Pregabalin as a Means to Prevent the Paclitaxel-Associated Acute Pain Syndrome
Status: Enrolling
Updated: 4/4/2018
Cancer Center of Kansas
mi
from
Wichita, KA
Click here to add this to my saved trials
Pregabalin in Preventing Acute Pain Syndrome in Patients Receiving Paclitaxel
RC11C3, Pilot Placebo-controlled Evaluation of Pregabalin as a Means to Prevent the Paclitaxel-Associated Acute Pain Syndrome
Status: Enrolling
Updated:  4/4/2018
Essentia Health Duluth CCOP
mi
from
Duluth, MN
Pregabalin in Preventing Acute Pain Syndrome in Patients Receiving Paclitaxel
RC11C3, Pilot Placebo-controlled Evaluation of Pregabalin as a Means to Prevent the Paclitaxel-Associated Acute Pain Syndrome
Status: Enrolling
Updated: 4/4/2018
Essentia Health Duluth CCOP
mi
from
Duluth, MN
Click here to add this to my saved trials
Pregabalin in Preventing Acute Pain Syndrome in Patients Receiving Paclitaxel
RC11C3, Pilot Placebo-controlled Evaluation of Pregabalin as a Means to Prevent the Paclitaxel-Associated Acute Pain Syndrome
Status: Enrolling
Updated:  4/4/2018
Marshfield Clinic - Marshfield Center
mi
from
Marshfield, WI
Pregabalin in Preventing Acute Pain Syndrome in Patients Receiving Paclitaxel
RC11C3, Pilot Placebo-controlled Evaluation of Pregabalin as a Means to Prevent the Paclitaxel-Associated Acute Pain Syndrome
Status: Enrolling
Updated: 4/4/2018
Marshfield Clinic - Marshfield Center
mi
from
Marshfield, WI
Click here to add this to my saved trials
Pregabalin in Preventing Acute Pain Syndrome in Patients Receiving Paclitaxel
RC11C3, Pilot Placebo-controlled Evaluation of Pregabalin as a Means to Prevent the Paclitaxel-Associated Acute Pain Syndrome
Status: Enrolling
Updated:  4/4/2018
The Mayo Clinic
mi
from
Rochester, MN
Pregabalin in Preventing Acute Pain Syndrome in Patients Receiving Paclitaxel
RC11C3, Pilot Placebo-controlled Evaluation of Pregabalin as a Means to Prevent the Paclitaxel-Associated Acute Pain Syndrome
Status: Enrolling
Updated: 4/4/2018
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Pregabalin in Preventing Acute Pain Syndrome in Patients Receiving Paclitaxel
RC11C3, Pilot Placebo-controlled Evaluation of Pregabalin as a Means to Prevent the Paclitaxel-Associated Acute Pain Syndrome
Status: Enrolling
Updated:  4/4/2018
Coborn Cancer Center at Saint Cloud Hospital
mi
from
Saint Cloud, MN
Pregabalin in Preventing Acute Pain Syndrome in Patients Receiving Paclitaxel
RC11C3, Pilot Placebo-controlled Evaluation of Pregabalin as a Means to Prevent the Paclitaxel-Associated Acute Pain Syndrome
Status: Enrolling
Updated: 4/4/2018
Coborn Cancer Center at Saint Cloud Hospital
mi
from
Saint Cloud, MN
Click here to add this to my saved trials
Pregabalin in Preventing Acute Pain Syndrome in Patients Receiving Paclitaxel
RC11C3, Pilot Placebo-controlled Evaluation of Pregabalin as a Means to Prevent the Paclitaxel-Associated Acute Pain Syndrome
Status: Enrolling
Updated:  4/4/2018
Missouri Valley Cancer Consortium
mi
from
Omaha, NE
Pregabalin in Preventing Acute Pain Syndrome in Patients Receiving Paclitaxel
RC11C3, Pilot Placebo-controlled Evaluation of Pregabalin as a Means to Prevent the Paclitaxel-Associated Acute Pain Syndrome
Status: Enrolling
Updated: 4/4/2018
Missouri Valley Cancer Consortium
mi
from
Omaha, NE
Click here to add this to my saved trials
The Genetic Characterization of Dementia
The Genetic Characterization of Dementia
Status: Enrolling
Updated:  4/4/2018
National Institute of Aging, Clinical Research Unit
mi
from
Baltimore, MD
The Genetic Characterization of Dementia
The Genetic Characterization of Dementia
Status: Enrolling
Updated: 4/4/2018
National Institute of Aging, Clinical Research Unit
mi
from
Baltimore, MD
Click here to add this to my saved trials
Where Does Hope Fit In? The Relationship Between Hope, Uncertainty, and Coping Efficacy in Mothers of Children With Duchenne/Becker Muscular Dystrophy
Where Does Hope Fit In? The Relationship Between Hope, Uncertainty, and Coping Efficacy in Mothers of Children With Duchenne/Becker Muscular Dystrophy
Status: Enrolling
Updated:  4/4/2018
National Human Genome Research Institute (NHGRI), 9000 Rockville Pike
mi
from
Bethesda, MD
Where Does Hope Fit In? The Relationship Between Hope, Uncertainty, and Coping Efficacy in Mothers of Children With Duchenne/Becker Muscular Dystrophy
Where Does Hope Fit In? The Relationship Between Hope, Uncertainty, and Coping Efficacy in Mothers of Children With Duchenne/Becker Muscular Dystrophy
Status: Enrolling
Updated: 4/4/2018
National Human Genome Research Institute (NHGRI), 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
People Presenting With Neurocysticercosis in North America
NACC 002: A Multicenter Prospective Natural History Study of Patients Presenting With Neurocysticercosis in North America
Status: Enrolling
Updated:  4/4/2018
University of California at San Francisco
mi
from
San Francisco, CA
People Presenting With Neurocysticercosis in North America
NACC 002: A Multicenter Prospective Natural History Study of Patients Presenting With Neurocysticercosis in North America
Status: Enrolling
Updated: 4/4/2018
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
People Presenting With Neurocysticercosis in North America
NACC 002: A Multicenter Prospective Natural History Study of Patients Presenting With Neurocysticercosis in North America
Status: Enrolling
Updated:  4/4/2018
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
People Presenting With Neurocysticercosis in North America
NACC 002: A Multicenter Prospective Natural History Study of Patients Presenting With Neurocysticercosis in North America
Status: Enrolling
Updated: 4/4/2018
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
People Presenting With Neurocysticercosis in North America
NACC 002: A Multicenter Prospective Natural History Study of Patients Presenting With Neurocysticercosis in North America
Status: Enrolling
Updated:  4/4/2018
U.T. Southwestern Medical Center
mi
from
Dallas, TX
People Presenting With Neurocysticercosis in North America
NACC 002: A Multicenter Prospective Natural History Study of Patients Presenting With Neurocysticercosis in North America
Status: Enrolling
Updated: 4/4/2018
U.T. Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
People Presenting With Neurocysticercosis in North America
NACC 002: A Multicenter Prospective Natural History Study of Patients Presenting With Neurocysticercosis in North America
Status: Enrolling
Updated:  4/4/2018
Univ of Washington
mi
from
Seattle, WA
People Presenting With Neurocysticercosis in North America
NACC 002: A Multicenter Prospective Natural History Study of Patients Presenting With Neurocysticercosis in North America
Status: Enrolling
Updated: 4/4/2018
Univ of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
In Vivo Imaging of Therapeutic Electric Current Flow
In Vivo Imaging of Therapeutic Electric Current Flow
Status: Enrolling
Updated:  4/4/2018
University of Florida
mi
from
Gainesville, FL
In Vivo Imaging of Therapeutic Electric Current Flow
In Vivo Imaging of Therapeutic Electric Current Flow
Status: Enrolling
Updated: 4/4/2018
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Evaluating the Indego Exoskeleton for Persons With Hemiplegia Due to CVA
Evaluating the Indego Exoskeleton for Persons With Hemiplegia Due to CVA
Status: Enrolling
Updated:  4/4/2018
Cedars-Sinai Health System
mi
from
Los Angeles, CA
Evaluating the Indego Exoskeleton for Persons With Hemiplegia Due to CVA
Evaluating the Indego Exoskeleton for Persons With Hemiplegia Due to CVA
Status: Enrolling
Updated: 4/4/2018
Cedars-Sinai Health System
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Evaluating the Indego Exoskeleton for Persons With Hemiplegia Due to CVA
Evaluating the Indego Exoskeleton for Persons With Hemiplegia Due to CVA
Status: Enrolling
Updated:  4/4/2018
Shepherd Center
mi
from
Atlanta, GA
Evaluating the Indego Exoskeleton for Persons With Hemiplegia Due to CVA
Evaluating the Indego Exoskeleton for Persons With Hemiplegia Due to CVA
Status: Enrolling
Updated: 4/4/2018
Shepherd Center
mi
from
Atlanta, GA
Click here to add this to my saved trials
Evaluating the Indego Exoskeleton for Persons With Hemiplegia Due to CVA
Evaluating the Indego Exoskeleton for Persons With Hemiplegia Due to CVA
Status: Enrolling
Updated:  4/4/2018
Rehabilitation Institute of Chicago (Shirley Ryan AbilityLab)
mi
from
Chicago, IL
Evaluating the Indego Exoskeleton for Persons With Hemiplegia Due to CVA
Evaluating the Indego Exoskeleton for Persons With Hemiplegia Due to CVA
Status: Enrolling
Updated: 4/4/2018
Rehabilitation Institute of Chicago (Shirley Ryan AbilityLab)
mi
from
Chicago, IL
Click here to add this to my saved trials
Evaluating the Indego Exoskeleton for Persons With Hemiplegia Due to CVA
Evaluating the Indego Exoskeleton for Persons With Hemiplegia Due to CVA
Status: Enrolling
Updated:  4/4/2018
Kessler Foundation
mi
from
West Orange, NJ
Evaluating the Indego Exoskeleton for Persons With Hemiplegia Due to CVA
Evaluating the Indego Exoskeleton for Persons With Hemiplegia Due to CVA
Status: Enrolling
Updated: 4/4/2018
Kessler Foundation
mi
from
West Orange, NJ
Click here to add this to my saved trials
Evaluating the Indego Exoskeleton for Persons With Hemiplegia Due to CVA
Evaluating the Indego Exoskeleton for Persons With Hemiplegia Due to CVA
Status: Enrolling
Updated:  4/4/2018
St. Charles Hospital
mi
from
Port Jefferson, NY
Evaluating the Indego Exoskeleton for Persons With Hemiplegia Due to CVA
Evaluating the Indego Exoskeleton for Persons With Hemiplegia Due to CVA
Status: Enrolling
Updated: 4/4/2018
St. Charles Hospital
mi
from
Port Jefferson, NY
Click here to add this to my saved trials
Evaluating the Indego Exoskeleton for Persons With Hemiplegia Due to CVA
Evaluating the Indego Exoskeleton for Persons With Hemiplegia Due to CVA
Status: Enrolling
Updated:  4/4/2018
TIRR Memorial Hermann
mi
from
Houston, TX
Evaluating the Indego Exoskeleton for Persons With Hemiplegia Due to CVA
Evaluating the Indego Exoskeleton for Persons With Hemiplegia Due to CVA
Status: Enrolling
Updated: 4/4/2018
TIRR Memorial Hermann
mi
from
Houston, TX
Click here to add this to my saved trials
Evaluating the Indego Exoskeleton for Persons With Hemiplegia Due to CVA
Evaluating the Indego Exoskeleton for Persons With Hemiplegia Due to CVA
Status: Enrolling
Updated:  4/4/2018
Sheltering Arms Physical Rehabilitation Centers
mi
from
Mechanicsville, VA
Evaluating the Indego Exoskeleton for Persons With Hemiplegia Due to CVA
Evaluating the Indego Exoskeleton for Persons With Hemiplegia Due to CVA
Status: Enrolling
Updated: 4/4/2018
Sheltering Arms Physical Rehabilitation Centers
mi
from
Mechanicsville, VA
Click here to add this to my saved trials
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Status: Enrolling
Updated:  4/5/2018
Clinical Research Facility
mi
from
Scottsdale, AZ
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Status: Enrolling
Updated: 4/5/2018
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Status: Enrolling
Updated:  4/5/2018
Clinical Research Facility
mi
from
San Francisco, CA
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Status: Enrolling
Updated: 4/5/2018
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Status: Enrolling
Updated:  4/5/2018
Clinical Research Facility
mi
from
Chicago, IL
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Status: Enrolling
Updated: 4/5/2018
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Status: Enrolling
Updated:  4/5/2018
Clinical Research Facility
mi
from
Portland, OR
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Status: Enrolling
Updated: 4/5/2018
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Status: Enrolling
Updated:  4/5/2018
Clinical Research Facility
mi
from
Seattle, WA
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Status: Enrolling
Updated: 4/5/2018
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis (Radiance Study)
A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  4/5/2018
Receptos Study Site 115
mi
from
Phoenix, AZ
Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis (Radiance Study)
A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 4/5/2018
Receptos Study Site 115
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis (Radiance Study)
A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  4/5/2018
Receptos Study Site 115
mi
from
Phoenix, AZ
Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis (Radiance Study)
A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 4/5/2018
Receptos Study Site 115
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis (Radiance Study)
A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  4/5/2018
Receptos Study Site 119
mi
from
Tucson, AZ
Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis (Radiance Study)
A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 4/5/2018
Receptos Study Site 119
mi
from
Tucson, AZ
Click here to add this to my saved trials
Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis (Radiance Study)
A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  4/5/2018
Receptos Study Site 110
mi
from
Berkeley, CA
Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis (Radiance Study)
A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 4/5/2018
Receptos Study Site 110
mi
from
Berkeley, CA
Click here to add this to my saved trials
Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis (Radiance Study)
A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  4/5/2018
Receptos Study Site 122
mi
from
Long Beach, CA
Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis (Radiance Study)
A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 4/5/2018
Receptos Study Site 122
mi
from
Long Beach, CA
Click here to add this to my saved trials
Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis (Radiance Study)
A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  4/5/2018
Receptos Study Site 112
mi
from
Sacramento, CA
Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis (Radiance Study)
A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 4/5/2018
Receptos Study Site 112
mi
from
Sacramento, CA
Click here to add this to my saved trials
Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis (Radiance Study)
A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  4/5/2018
Receptos Study Site 120
mi
from
San Francisco, CA
Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis (Radiance Study)
A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 4/5/2018
Receptos Study Site 120
mi
from
San Francisco, CA
Click here to add this to my saved trials
Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis (Radiance Study)
A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  4/5/2018
Receptos Study Site 127
mi
from
Denver, CO
Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis (Radiance Study)
A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 4/5/2018
Receptos Study Site 127
mi
from
Denver, CO
Click here to add this to my saved trials
Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis (Radiance Study)
A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  4/5/2018
Receptos Study Site 114
mi
from
Maitland, FL
Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis (Radiance Study)
A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 4/5/2018
Receptos Study Site 114
mi
from
Maitland, FL
Click here to add this to my saved trials
Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis (Radiance Study)
A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  4/5/2018
Receptos Study Site 124
mi
from
Pompano Beach, FL
Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis (Radiance Study)
A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 4/5/2018
Receptos Study Site 124
mi
from
Pompano Beach, FL
Click here to add this to my saved trials
Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis (Radiance Study)
A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  4/5/2018
Receptos Study Site 123
mi
from
Port Charlotte, FL
Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis (Radiance Study)
A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 4/5/2018
Receptos Study Site 123
mi
from
Port Charlotte, FL
Click here to add this to my saved trials
Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis (Radiance Study)
A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  4/5/2018
Receptos Study Site 113
mi
from
Northbrook, IL
Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis (Radiance Study)
A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 4/5/2018
Receptos Study Site 113
mi
from
Northbrook, IL
Click here to add this to my saved trials
Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis (Radiance Study)
A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  4/5/2018
Receptos Study Site 101
mi
from
Charlotte, NC
Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis (Radiance Study)
A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 4/5/2018
Receptos Study Site 101
mi
from
Charlotte, NC
Click here to add this to my saved trials
Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis (Radiance Study)
A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  4/5/2018
Receptos Study Site 107
mi
from
Akron, OH
Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis (Radiance Study)
A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 4/5/2018
Receptos Study Site 107
mi
from
Akron, OH
Click here to add this to my saved trials
Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis (Radiance Study)
A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  4/5/2018
Receptos Study Site 104
mi
from
Cleveland, OH
Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis (Radiance Study)
A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 4/5/2018
Receptos Study Site 104
mi
from
Cleveland, OH
Click here to add this to my saved trials
Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis (Radiance Study)
A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  4/5/2018
Receptos Study Site 109
mi
from
Philadelphia, PA
Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis (Radiance Study)
A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 4/5/2018
Receptos Study Site 109
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis (Radiance Study)
A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  4/5/2018
Receptos Study Site 102
mi
from
Seattle, WA
Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis (Radiance Study)
A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 4/5/2018
Receptos Study Site 102
mi
from
Seattle, WA
Click here to add this to my saved trials
Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis (Radiance Study)
A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  4/5/2018
Receptos Study Site 125
mi
from
Tacoma, WA
Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis (Radiance Study)
A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 4/5/2018
Receptos Study Site 125
mi
from
Tacoma, WA
Click here to add this to my saved trials
Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis (Radiance Study)
A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  4/5/2018
Receptos Study Site 121
mi
from
Saint Louis, MO
Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis (Radiance Study)
A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 4/5/2018
Receptos Study Site 121
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis (Radiance Study)
A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  4/5/2018
Xenoscience Inc.
mi
from
Phoenix, AZ
Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis (Radiance Study)
A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 4/5/2018
Xenoscience Inc.
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis (Radiance Study)
A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  4/5/2018
Saint Josephs Hosptial and Medical Center
mi
from
Phoenix, AZ
Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis (Radiance Study)
A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 4/5/2018
Saint Josephs Hosptial and Medical Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials